251 related articles for article (PubMed ID: 6285731)
21. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
[TBL] [Abstract][Full Text] [Related]
22. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
23. Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds.
Smith KO; Galloway KS; Ogilvie KK; Cheriyan UO
Antimicrob Agents Chemother; 1982 Dec; 22(6):1026-30. PubMed ID: 6297382
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Wilber BA; Docherty JJ
J Gen Virol; 1994 Jul; 75 ( Pt 7)():1743-7. PubMed ID: 8021603
[TBL] [Abstract][Full Text] [Related]
25. Analysis of toxic and mutagenic activities of antiherpesvirus nucleosides against HeLa cells and herpes simplex virus type 1.
Suzutani T; Machida H
Mutat Res; 1992 May; 267(1):125-31. PubMed ID: 1373847
[TBL] [Abstract][Full Text] [Related]
26. Antiviral activity of ganciclovir elaidic acid ester against herpesviruses.
Andrei G; Snoeck R; Neyts J; Sandvold ML; Myhren F; De Clercq E
Antiviral Res; 2000 Mar; 45(3):157-67. PubMed ID: 10771080
[TBL] [Abstract][Full Text] [Related]
27. Problems associated with the use of (E)-5-(2-bromovinyl)-2'-deoxyuridine for typing herpes simplex virus.
Swierkosz EM; Arens MQ; Rivetna KA
J Clin Microbiol; 1985 Mar; 21(3):459-61. PubMed ID: 2984249
[TBL] [Abstract][Full Text] [Related]
28. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome.
Birch CJ; Tachedjian G; Doherty RR; Hayes K; Gust ID
J Infect Dis; 1990 Sep; 162(3):731-4. PubMed ID: 2167340
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet.
Bleymehl K; Cinatl J; Schmidt-Chanasit J
Med Microbiol Immunol; 2011 Aug; 200(3):193-202. PubMed ID: 21373931
[TBL] [Abstract][Full Text] [Related]
30. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
Birch CJ; Tyssen DP; Tachedjian G; Doherty R; Hayes K; Mijch A; Lucas CR
J Infect Dis; 1992 Jul; 166(1):108-12. PubMed ID: 1318909
[TBL] [Abstract][Full Text] [Related]
31. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2.
Balzarini J; Bohman C; De Clercq E
J Biol Chem; 1993 Mar; 268(9):6332-7. PubMed ID: 8384209
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy of herpetic keratitis induced by acyclovir-resistant strains of herpes simplex virus type 1.
O'Brien WJ; Taylor JL
Am J Med; 1982 Jul; 73(1A):294-9. PubMed ID: 6285720
[TBL] [Abstract][Full Text] [Related]
33. Effect of genetically determined host factors on the efficacy of vidarabine, acyclovir and 5-trifluorothymidine in herpes simplex virus type 1 infection.
Abghari SZ; Stulting RD; Zhu Z; Schinazi RF; Kaufman HE
Ophthalmic Res; 1994; 26(2):95-104. PubMed ID: 8196938
[TBL] [Abstract][Full Text] [Related]
34. Prolonged herpes simplex virus latency in vitro after treatment of infected cells with acyclovir and human leukocyte interferon.
Scheck AC; Wigdahl B; De Clercq E; Rapp F
Antimicrob Agents Chemother; 1986 Apr; 29(4):589-93. PubMed ID: 3010847
[TBL] [Abstract][Full Text] [Related]
35. Properties of antiviral agents. 1.
Nicholson KG
Lancet; 1984 Sep; 2(8401):503-6. PubMed ID: 6147558
[No Abstract] [Full Text] [Related]
36. Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease.
Charles SJ; Gray JJ
Br J Ophthalmol; 1990 May; 74(5):286-8. PubMed ID: 2162190
[TBL] [Abstract][Full Text] [Related]
37. Comparative activities of selected combinations of acyclovir, vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice.
Crane LR; Milne DA; Sunstrum JC; Lerner AM
Antimicrob Agents Chemother; 1984 Oct; 26(4):557-62. PubMed ID: 6083754
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2.
Ayisi NK; Gupta VS; Meldrum JB; Taneja AK; Babiuk LA
Antimicrob Agents Chemother; 1980 Apr; 17(4):558-66. PubMed ID: 6249191
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid.
Derse D; Bastow KF; Cheng Y
J Biol Chem; 1982 Sep; 257(17):10251-60. PubMed ID: 6286645
[TBL] [Abstract][Full Text] [Related]
40. Biochemical and genetic analysis of acyclovir-resistant mutants of herpes simplex virus type 1.
Coen DM; Schaffer PA; Furman PA; Keller PM; St Clair MH
Am J Med; 1982 Jul; 73(1A):351-60. PubMed ID: 6285722
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
